(Z)-N'-(2-chloroacetoxy)-4-chlorobenzimidamide | 93048-83-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (Z)-N'-(2-chloroacetoxy)-4-chlorobenzimidamide
• 英文别名: [(Z)-[amino-(4-chlorophenyl)methylidene]amino] 2-chloroacetate
• CAS: 93048-83-0
• 化学式: C₉H₈Cl₂N₂O₂
• 分子量: 247.081
• InChiKey: PKCVQMWJUHGXGA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  64.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (Z)-N'-(2-chloroacetoxy)-4-chlorobenzimidamide 在 potassium carbonate 、 三乙胺 作用下， 以 四氢呋喃 、 甲苯 、 乙腈 为溶剂， 反应 2.75h， 生成 2-(4-chlorophenoxy)-N-((3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl)methyl)-N-isopropylacetamide
  参考文献：
  名称：

  恶二唑-异丙基酰胺作为有效的非共价蛋白酶体抑制剂

  摘要：

  对 50 000 ChemBridge 化合物库的筛选导致鉴定出恶二唑-异丙基酰胺1 (PI-1833)，其抑制胰凝乳蛋白酶样 (CT-L) 活性（IC 50 = 0.60 μM），对其他两种主要蛋白酶体几乎没有影响蛋白水解活性，胰蛋白酶样 (TL) 和谷氨酰肽水解样 (PGPH-L)。LC-MS/MS 和透析表明1是一种非共价且快速可逆的 CT-L 抑制剂。集中文库合成为11ad (PI-1840) 提供了 CT-L 活性 (IC 50= 27 纳米）。详细的 SAR 研究表明酰胺部分和两个苯环对修饰敏感。疏水性残基，如在对位丙基或丁基（未邻位或间位）的A环和一个的米-吡啶基团作为B环，显著提高活性。化合物11ad (IC 50 = 0.37 μM)在抑制完整 MDA-MB-468 人乳腺癌细胞中的 CT-L 活性和抑制其存活方面比1 (IC 50 = 3.5 μM)更有效。11ad的活

  DOI：

  10.1021/jm400221d
• 作为产物：
  描述：

  苯甲腈 在 8-羟基喹啉 、 盐酸羟胺 、 sodium carbonate 、 potassium carbonate 作用下， 以 乙醇 、 二氯甲烷 、 水 为溶剂， 反应 3.0h， 生成 (Z)-N'-(2-chloroacetoxy)-4-chlorobenzimidamide
  参考文献：
  名称：

  Antikinetoplastid activity of 3-aryl-5-thiocyanatomethyl-1,2,4-oxadiazoles

  摘要：

  A series of 5-thiocyanatomethyl- and 5-alkyl-3-aryl-1,2,4-oxadiazoles were synthesized and evaluated for their activity against kinetoplastid parasites. Formation of the oxadiazole ring was accomplished through the reaction of benzamidoximes with acyl chlorides, while the thiocyanate group was inserted by reacting the appropriate 5-halomethyl oxadiazole with ammonium thiocyanate. The thiocyanate-containing compounds possessed low micromolar activity against Leishmania donovani and Trypanosoma brucei, while the 5-alkyl oxadiazoles were less active against these parasites. 3-(4-Chlorophenyl)-5-(thiocyanatomethyl)-1,2,4-oxadiazole (compound 4b) displayed modest selectivity for L. donovani axenic amastigote-like parasites over J774 macrophages, PC3 prostate cancer cells, and Vero cells (6.4-fold, 3.8-fold, and 9.1-fold, respectively), while 3-(3,4-dichlorophenyl)-5-(thiocyanatomethyl)-1,2,4-oxadiazole (compound 4h) showed 30-fold selectivity against Vero cells but was not selective against PC3 cells. In a murine model of visceral leishmaniasis, compound 4b decreased liver parasitemia caused by L. donovani by 48% when given in five daily i.v. doses at 5 mg/kg and by 61 % when administered orally for 5 days at 50 mg/kg. These results indicate that aromatic thiocyanates hold promise for the treatment of leishmanial infections if the selectivity of these compounds can be improved. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2004.03.054

文献信息

• Design, Synthesis, Biological Evaluation, and Docking Study of Acetylcholinesterase Inhibitors: New Acridone-1,2,4-oxadiazole-1,2,3-triazole Hybrids
  作者：Maryam Mohammadi-Khanaposhtani、Mohammad Mahdavi、Mina Saeedi、Reyhaneh Sabourian、Maliheh Safavi、Mahnaz Khanavi、Alireza Foroumadi、Abbas Shafiee、Tahmineh Akbarzadeh

  DOI：10.1111/cbdd.12609

  日期：2015.12

  this study, novel acridone‐1,2,4‐oxadiazole‐1,2,3‐triazole hybrids were designed, synthesized, and evaluated for their acetylcholinesterase and butyrylcholinesterase inhibitory activity. Among various synthesized compounds, 10‐((1‐((3‐(4‐methoxyphenyl)‐1,2,4‐oxadiazol‐5‐yl)methyl)‐1H‐1,2,3‐triazol‐4‐yl)methyl)acridin‐9(10H)‐one 10b showed the most potent anti‐acetylcholinesterase activity (IC50 = 11.55 μm)

  在这项研究中，设计，合成并评估了新的a啶酮1,2,4，恶二唑1,2,3-三唑杂合体的乙酰胆碱酯酶和丁酰胆碱酯酶抑制活性。在各种合成的化合物中，10-（（1-（（3-（4--甲氧基苯基）-1,2,4-恶二唑-5-基）甲基）-1 H -1,2,3-三唑-4-基）甲基）吖啶-9-（10 ħ） -酮10b中显示出最有效的抗乙酰胆碱酯酶活性（IC 50  = 11.55  μ米）是一样有效的利凡斯的明。对接结果也与体外结果高度吻合，证实了化合物10b的双重结合抑制活性。
• Design, synthesis, pharmacological evaluation, and docking study of new acridone-based 1,2,4-oxadiazoles as potential anticonvulsant agents
  作者：Maryam Mohammadi-Khanaposhtani、Mohammad Shabani、Mehrdad Faizi、Iraj Aghaei、Reza Jahani、Zainab Sharafi、Narges Shamsaei Zafarghandi、Mohammad Mahdavi、Tahmineh Akbarzadeh、Saeed Emami、Abbas Shafiee、Alireza Foroumadi

  DOI：10.1016/j.ejmech.2016.01.054

  日期：2016.4

  number of acridone-based oxadiazoles 11a–n have been synthesized and evaluated for their anticonvulsant activity against pentylenetetrazole (PTZ)- and maximal electroshock (MES)-induced seizures in mice. Also, their neurotoxicity was evaluated by the rotarod test. Most of the compounds exhibited better anticonvulsant activity and higher safety respect to the standard drug, phenobarbital. Among the tested

  已经合成了许多基于cri啶酮的恶二唑11a–n，它们对戊戊四唑（PTZ）和最大电击（MES）引起的癫痫发作具有抗惊厥作用。另外，通过旋转脚踏试验评估了它们的神经毒性。相对于标准药物苯巴比妥，大多数化合物表现出更好的抗惊厥活性和更高的安全性。在测试的衍生物中，ED 50值为2.08 mg / kg的化合物11l是PTZ测试中最有效的化合物。氟马西尼阻断了化合物11l的抗惊厥作用，表明苯二氮卓（BZD）受体参与了原型化合物11l的抗惊厥活性。同样，化合物11l与GABA A受体的BZD结合位点的对接研究证实了化合物11l与BZD受体的可能结合。
• PROTEASOME CHYMOTRYPSIN-LIKE INHIBITION USING PI-1833 ANALOGS
  申请人：H. Lee Moffitt Cancer Center and Research Institute, Inc

  公开号：US20140073650A1

  公开（公告）日：2014-03-13

  Focused library synthesis and medicinal chemistry on an oxadiazole-isopropylamide core proteasome inhibitor provided the lead compound that strongly inhibits CT-L activity. Structure activity relationship studies indicate the amide moiety and two phenyl rings are sensitive toward synthetic modifications. Only para-substitution in the A-ring was important to maintain potent CT-L inhibitory activity. Hydrophobic residues in the A-ring's para-position and meta-pyridyl group at the B-ring significantly improved inhibition. The meta-pyridyl moiety improved cell permeability. The length of the aliphatic chain at the para position of the A-ring is critical with propyl yielding the most potent inhibitor, whereas shorter (i.e. ethyl, methyl or hydrogen) or longer (i.e. butyl, propyl and hexyl) chains demonstrating progressively less potency. Introduction of a stereogenic center next to the ether moiety (i.e. substitution of one of the hydrogens by methyl) demonstrated chiral discrimination in proteasome CT-L activity inhibition (the S-enantiomer was 35-40 fold more potent than the R-enantiomer).

  聚焦于氧代二唑-异丙酰胺核心蛋白酶体抑制剂的合成和药物化学，提供了一种强烈抑制CT-L活性的先导化合物。结构活性关系研究表明，酰胺基团和两个苯环对合成修饰非常敏感。只有在A环上的对位取代对维持强效的CT-L抑制活性至关重要。A环对位的疏水基团和B环的间吡啶基团显著提高了抑制作用。间吡啶基团提高了细胞渗透性。A环对位的脂肪链长度是关键，丙基产生了最有效的抑制剂，而较短（即乙基，甲基或氢）或较长（即丁基，异丙基和己基）的链逐渐表现出较少的效力。在醚基团旁引入一个立体异构中心（即将一个氢原子取代为甲基）表明在蛋白酶体CT-L活性抑制中具有手性歧视（S-对映体比R-对映体更有效，效力提高了35-40倍）。
• Synthesis, in silico and in vitro evaluation of new 3,5-disubstituted-1,2,4-oxadiazole derivatives as carbonic anhydrase inhibitors and cytotoxic agents
  作者：Kaan Kucukoglu、Nagihan Faydali、Dilek Bul、Hayrunnisa Nadaroglu、Belgin Sever、Mehlika Dilek Altıntop、Bahadır Ozturk、Ilkay Guzel

  DOI：10.1016/j.molstruc.2022.134699

  日期：2023.3

  In this work, new 3,5-disubstituted-1,2,4-oxadiazoles were synthesized efficiently and evaluated for their inhibitory effects on human carbonic anhydrase (hCA) I and II. Most of them were more potent on hCAs than acetazolamide (AAZ). Compounds 10d and 17d were the most potent compounds on hCA I with IC50 values of 0.68 and 0.96 µM, respectively. Compounds 7d, 17d, 10d, and 3d were the most effective

  在这项工作中，高效合成了新的 3,5-二取代-1,2,4-恶二唑，并评估了它们对人碳酸酐酶 (hCA) I 和 II 的抑制作用。它们中的大多数对 hCAs 比乙酰唑胺 (AAZ) 更有效。化合物10d和17d是对 hCA I 最有效的化合物，IC 50值分别为 0.68 和 0.96 µM。化合物7d、17d、10d和3d是最有效的 hCA II 抑制剂，IC 50值为 0.40、0.40、0.65 和 0.71 µM。分子对接研究表明，化合物10d和17d在 hCA I 的活性位点显示出与 Phe91 的 π-π 堆积相互作用。化合物10d和17d能够在 hCA II 的活性位点与 His94 形成 π-π 堆积相互作用，并与 Phe131 形成 π-阳离子相互作用。两种化合物的烷基氨基对 hCA II 活性位点的关键相互作用都有贡献。根据计算机数据，预测所有化合物都具有良好的口服生物
• Synthesis of [4-(3-aryl-1,2,4-oxadiazol-5-ylmethylthio)-2-methylphenoxy]acetic acids as new potential PPAR agonists
  作者：D. V. Minin、S. V. Popkov、K. V. Pesochinskaya、D. R. Aleksanov

  DOI：10.1007/s11172-023-3944-5

  日期：2023.7

  A five-step synthetic route to [4-(3-aryl-1,2,4-oxadiazol-5-ylmethylthio)-2-methyl-phenoxy]acetic acids, new potential agonists of type δ/β peroxisome proliferator-activated receptors (PPARδ/β), starting from substituted benzonitriles was developed.

  [4-(3-芳基-1,2,4-恶二唑-5-基甲硫基)-2-甲基-苯氧基]乙酸的五步合成路线，δ/β型过氧化物酶体增殖物激活受体的新潜在激动剂(PPARδ/β)，从取代的苯甲腈开始开发。